303 related articles for article (PubMed ID: 17576560)
21. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
22. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
23. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.
Chang MH; Kim KH; Jun HJ; Kim HS; Yi SY; Uhm JE; Park MJ; Lim DH; Ji SH; Hwang IG; Lee J; Park YH; Ahn JS; Ahn MJ; Park K
Cancer Chemother Pharmacol; 2009 Oct; 64(5):917-24. PubMed ID: 19221753
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
Sohn JH; Choi HJ; Chang J; Kim SK; Lee CG; Chung KY; Kim DJ; Cho BC; Shin SJ; Moon YW; Kim JH
Lung Cancer; 2006 Dec; 54(3):365-70. PubMed ID: 17011068
[TBL] [Abstract][Full Text] [Related]
26. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
Perez-Soler R; Glisson BS; Lee JS; Fossella FV; Murphy WK; Shin DM; Hong WK
J Clin Oncol; 1996 Oct; 14(10):2785-90. PubMed ID: 8874340
[TBL] [Abstract][Full Text] [Related]
27. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V
Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313
[TBL] [Abstract][Full Text] [Related]
28. Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients.
Jacot W; Pujol JL; Chakra M; Molinier O; Bozonnat MC; Gervais R; Quantin X
Lung Cancer; 2012 Feb; 75(2):213-6. PubMed ID: 21831476
[TBL] [Abstract][Full Text] [Related]
29. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
Ardizzoni A; Hansen H; Dombernowsky P; Gamucci T; Kaplan S; Postmus P; Giaccone G; Schaefer B; Wanders J; Verweij J
J Clin Oncol; 1997 May; 15(5):2090-6. PubMed ID: 9164222
[TBL] [Abstract][Full Text] [Related]
30. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.
Jeong J; Cho BC; Sohn JH; Choi HJ; Kim SH; Lee YJ; Jung MK; Shin SJ; Park MS; Kim SK; Chang J; Kim JH
Lung Cancer; 2010 Oct; 70(1):77-81. PubMed ID: 20138389
[TBL] [Abstract][Full Text] [Related]
31. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
[TBL] [Abstract][Full Text] [Related]
33. Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
Pectasides D; Samantas E; Fountzilas G; Briasoulis E; Kosmidis P; Skarlos D; Dimopoulos MA; Kalofonos HP; Economopoulos T; Syrigos K
Lung Cancer; 2007 Dec; 58(3):355-61. PubMed ID: 17698241
[TBL] [Abstract][Full Text] [Related]
34. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
[TBL] [Abstract][Full Text] [Related]
37. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study.
Ichiki M; Gohara R; Rikimaru T; Kitajima T; Fujiki R; Shimada A; Aizawa H
Chemotherapy; 2003 Jul; 49(4):200-5. PubMed ID: 12886056
[TBL] [Abstract][Full Text] [Related]
38. [Combination of irinotecan hydrochloride and etoposide for treatment of refractory or relapsed small-cell lung cancer].
Negoro S; Masuda N
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1105-8. PubMed ID: 10945003
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
Lee JE; Park HS; Jung SS; Kim JO; Kim SY
Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
[TBL] [Abstract][Full Text] [Related]
40. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
